1. Home
  2. SNGX vs EVAX Comparison

SNGX vs EVAX Comparison

Compare SNGX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.37

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$4.77

Market Cap

42.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
EVAX
Founded
1987
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
42.7M
IPO Year
1987
2021

Fundamental Metrics

Financial Performance
Metric
SNGX
EVAX
Price
$1.37
$4.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$12.33
AVG Volume (30 Days)
455.3K
105.1K
Earning Date
11-07-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,650,000.00
Revenue This Year
N/A
$128.77
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.17
52 Week Low
$1.09
$1.20
52 Week High
$6.23
$12.15

Technical Indicators

Market Signals
Indicator
SNGX
EVAX
Relative Strength Index (RSI) 42.82 39.17
Support Level $1.20 $5.72
Resistance Level $1.70 $6.70
Average True Range (ATR) 0.12 0.52
MACD -0.03 -0.07
Stochastic Oscillator 33.33 5.22

Price Performance

Historical Comparison
SNGX
EVAX

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

Share on Social Networks: